Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2190

1.

A heavy metal baseline score predicts outcome in AML.

Ohanian M, Telouk P, Kornblau S, Albarede F, Ruvolo P, Tidwell RSS, Plesa A, Kanagal-Shamanna R, Matera EL, Cortes J, Carson A, Dumontet C.

Am J Hematol. 2020 Jan 16. doi: 10.1002/ajh.25731. [Epub ahead of print]

PMID:
31944361
2.

Brain connectivity and cognitive functioning in individuals six months after multiorgan failure.

Jimenez-Marin A, Rivera D, Boado V, Diez I, Labayen F, Garrido I, Ramos-Usuga D, Benito-Sánchez I, Rasero J, Cabrera-Zubizarreta A, Gabilondo I, Stramaglia S, Arango-Lasprilla JC, Cortes JM.

Neuroimage Clin. 2019 Dec 23;25:102137. doi: 10.1016/j.nicl.2019.102137. [Epub ahead of print]

3.

Efficacy of PI3K inhibitors in advanced breast cancer.

Verret B, Cortes J, Bachelot T, Andre F, Arnedos M.

Ann Oncol. 2019 Dec;30 Suppl 10:x12-x20. doi: 10.1093/annonc/mdz381. Review.

PMID:
31928690
4.

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH Jr, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, Press RD, Raess PW, Cascio M, Dunlap J, Chen Y, Degnin C, Maxson JE, Tognon CE, Macey T, Druker BJ, Tyner JW.

J Clin Oncol. 2019 Dec 27:JCO1900895. doi: 10.1200/JCO.19.00895. [Epub ahead of print]

PMID:
31880950
5.

Efficacy of PI3K inhibitors in advanced breast cancer.

Verret B, Cortes J, Bachelot T, Andre F, Arnedos M.

Ann Oncol. 2019 Dec 1;30(Supplement_10):x12-x20. doi: 10.1093/annonc/mdz381.

6.

Predictive clinical features of cardioembolic infarction in patients aged 85 years and older.

Carbajo-García AM, Cortés J, Arboix A, Massons J, Díez L, Vergés E, Arboix-Alió J, García-Eroles L.

J Geriatr Cardiol. 2019 Nov;16(11):793-799. doi: 10.11909/j.issn.1671-5411.2019.11.008.

7.

Treatment-free remission in chronic myeloid leukemia.

Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ.

Clin Adv Hematol Oncol. 2019 Dec;17(12):686-696.

PMID:
31851157
8.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC.

J Clin Oncol. 2019 Dec 16:JCO1900368. doi: 10.1200/JCO.19.00368. [Epub ahead of print]

PMID:
31841354
9.

Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma.

Nunes-Xavier CE, Aurtenetxe O, Zaldumbide L, López-Almaraz R, Erramuzpe A, Cortés JM, López JI, Pulido R.

Diagn Pathol. 2019 Dec 14;14(1):134. doi: 10.1186/s13000-019-0919-9.

10.

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.

Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA.

J Clin Med. 2019 Dec 11;8(12). pii: E2180. doi: 10.3390/jcm8122180.

11.

Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.

Cortés J, Ciruelos E, Pérez-García J, Albanell J, García-Estévez L, Ruiz-Borrego M, Espinosa R, Gallegos I, González S, Álvarez I, Llombart A.

Cancer Treat Rev. 2019 Nov 29;83:101944. doi: 10.1016/j.ctrv.2019.101944. [Epub ahead of print] Review.

PMID:
31830538
12.

Investigation of Lewis Acid-Carbonyl Solution Interactions via Infrared-Monitored Titration.

Hanson CS, Psaltakis MC, Cortes JJ, Siddiqi SS, Devery JJ 3rd.

J Org Chem. 2019 Dec 27. doi: 10.1021/acs.joc.9b02822. [Epub ahead of print]

PMID:
31830419
13.

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, Janssen JJWM, Mahon FX, Minami Y, Yeung D, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse KG, Lang F, Kim DW.

N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.

PMID:
31826340
14.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators.

N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914510. [Epub ahead of print]

PMID:
31825192
15.

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.

Jacobs SA, Robidoux A, Abraham J, Pérez-Garcia JM, La Verde N, Orcutt JM, Cazzaniga ME, Piette F, Antolín S, Aguirre E, Cortes J, Llombart-Cussac A, Di Cosimo S, Kim RS, Feng H, Lipchik C, Lucas PC, Srinivasan A, Wang Y, Song N, Gavin PG, Balousek AD, Paik S, Allegra CJ, Wolmark N, Pogue-Geile KL.

Breast Cancer Res. 2019 Dec 3;21(1):133. doi: 10.1186/s13058-019-1196-y.

16.

Regional brain atrophy in gray and white matter is associated with cognitive impairment in Myotonic Dystrophy type 1.

Labayru G, Diez I, Sepulcre J, Fernández E, Zulaica M, Cortés JM, López de Munain A, Sistiaga A.

Neuroimage Clin. 2019;24:102078. doi: 10.1016/j.nicl.2019.102078. Epub 2019 Nov 6.

17.
18.

Clinical Implications of Extracellular HMGA1 in Breast Cancer.

Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J.

Int J Mol Sci. 2019 Nov 26;20(23). pii: E5950. doi: 10.3390/ijms20235950. Review.

19.

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors.

Lin S, Shaik N, Martinelli G, Wagner AJ, Cortes J, Ruiz-Garcia A.

J Clin Pharmacol. 2019 Nov 25. doi: 10.1002/jcph.1556. [Epub ahead of print]

PMID:
31769065
20.

Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.

Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK.

Leuk Lymphoma. 2019 Nov 25:1-10. doi: 10.1080/10428194.2019.1688320. [Epub ahead of print]

PMID:
31760835
21.

Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.

Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian H, Garcia-Manero G.

Cancer. 2019 Nov 19. doi: 10.1002/cncr.32566. [Epub ahead of print]

PMID:
31742675
22.

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML).

Lindsley RC, Gibson CJ, Murdock HM, Stone RM, Cortes JE, Uy GL, Lin TL, Ritchie EK, Prebet T, Ryan RJ, Faderl S, Lancet JE.

Blood. 2019 Nov 13;134(Supplement_1):15. doi: 10.1182/blood-2019-124500.

PMID:
31723998
23.

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, Germing U, Onida F, Padron E, Platzbecker U, Santini V, Sanz GF, Solary E, Van de Loosdrecht A, Malcovati L.

Hemasphere. 2018 Nov 29;2(6):e150. doi: 10.1097/HS9.0000000000000150. eCollection 2018 Dec.

24.

Prey and Venom Efficacy of Male and Female Wandering Spider, Phoneutria boliviensis (Araneae: Ctenidae).

Valenzuela-Rojas JC, González-Gómez JC, van der Meijden A, Cortés JN, Guevara G, Franco LM, Pekár S, García LF.

Toxins (Basel). 2019 Oct 27;11(11). pii: E622. doi: 10.3390/toxins11110622.

25.

New records of Swiftia (Cnidaria, Anthozoa, Octocorallia) from off the Pacific Costa Rican margin, including a new species from methane seeps.

Breedy O, Rouse GW, Stabbins A, Cortés J, Cordes EE.

Zootaxa. 2019 Sep 18;4671(3):zootaxa.4671.3.6. doi: 10.11646/zootaxa.4671.3.6.

PMID:
31716045
26.

Corrigendum to "Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients" [Clin. Biomech. volume 68 (2019) Pages 169-174/Article Number JCLB 4795].

Olmos CMF, Alvarez-Calderon O, Marín DH, Cortés JI, Marco CP, Ivorra JAR.

Clin Biomech (Bristol, Avon). 2019 Nov 7. pii: S0268-0033(19)30813-7. doi: 10.1016/j.clinbiomech.2019.10.023. [Epub ahead of print] No abstract available.

PMID:
31708261
27.

The nucleus does not significantly affect the migratory trajectories of amoeba in two-dimensional environments.

De la Fuente IM, Bringas C, Malaina I, Regner B, Pérez-Samartín A, Boyano MD, Fedetz M, López JI, Pérez-Yarza G, Cortes JM, Sejnowski T.

Sci Rep. 2019 Nov 8;9(1):16369. doi: 10.1038/s41598-019-52716-2.

28.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.

Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E.

Am J Hematol. 2020 Feb;95(2):144-150. doi: 10.1002/ajh.25671. Epub 2019 Nov 19.

PMID:
31682008
29.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

PMID:
31665578
30.

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.

Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, Cortés J, Moltó-Abad M, Muñoz-Delgado C, Pérez-Quintana M, Pérez-López J.

Orphanet J Rare Dis. 2019 Oct 21;14(1):230. doi: 10.1186/s13023-019-1202-6.

31.

Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G.

Clin Cancer Res. 2020 Jan 15;26(2):354-363. doi: 10.1158/1078-0432.CCR-19-1164. Epub 2019 Oct 16.

PMID:
31619444
32.

Two S. pombe septation phases differ in ingression rate, septum structure, and response to F-actin loss.

Ramos M, Cortés JCG, Sato M, Rincón SA, Moreno MB, Clemente-Ramos JÁ, Osumi M, Pérez P, Ribas JC.

J Cell Biol. 2019 Dec 2;218(12):4171-4194. doi: 10.1083/jcb.201808163. Epub 2019 Oct 9.

PMID:
31597680
33.

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.

Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mouron S.

Clin Cancer Res. 2020 Jan 1;26(1):35-45. doi: 10.1158/1078-0432.CCR-19-2023. Epub 2019 Oct 9.

PMID:
31597662
34.

Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.

Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F.

Am J Hematol. 2019 Dec;94(12):1388-1395. doi: 10.1002/ajh.25648. Epub 2019 Oct 21.

PMID:
31595534
35.

NK-lysin, dicentracin and hepcidin antimicrobial peptides in European sea bass. Ontogenetic development and modulation in juveniles by nodavirus.

Valero Y, Arizcun M, Cortés J, Ramírez-Cepeda F, Guzmán F, Mercado L, Esteban MÁ, Chaves-Pozo E, Cuesta A.

Dev Comp Immunol. 2020 Feb;103:103516. doi: 10.1016/j.dci.2019.103516. Epub 2019 Oct 5.

PMID:
31593708
36.

Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia.

Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, Cortes J, Pemmaraju N.

Br J Haematol. 2019 Nov;187(4):543-545. doi: 10.1111/bjh.16245. Epub 2019 Oct 4. No abstract available.

PMID:
31584727
37.

Corrigendum to: -PTEN activity defines an axis for plasticity at cortico-amygdala synapses and influences social behavior.

Sánchez-Puelles C, Calleja-Felipe M, Ouro A, Bougamra G, Arroyo A, Diez I, Erramuzpe A, Cortés J, Martínez-Hernández J, Luján R, Navarrete M, Venero C, Chan A, Morales M, Esteban JA, Knafo S.

Cereb Cortex. 2019 Sep 27. pii: bhz232. doi: 10.1093/cercor/bhz232. [Epub ahead of print] No abstract available.

PMID:
31560052
38.

Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM.

Cancer. 2020 Jan 1;126(1):67-75. doi: 10.1002/cncr.32504. Epub 2019 Sep 25.

PMID:
31553487
39.

Comparison of polyspecific versus IgG specific ELISA in predominately cardiac patients with suspected heparin induced thrombocytopenia.

Samuel S, McGuire MF, Cortes J, Escobar M, Weeks P, Nguyen A.

J Thromb Thrombolysis. 2020 Jan;49(1):27-33. doi: 10.1007/s11239-019-01957-z.

PMID:
31552545
40.

Metastable Resting State Brain Dynamics.

Beim Graben P, Jimenez-Marin A, Diez I, Cortes JM, Desroches M, Rodrigues S.

Front Comput Neurosci. 2019 Sep 6;13:62. doi: 10.3389/fncom.2019.00062. eCollection 2019.

41.

Breast cancer.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F.

Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. Review.

PMID:
31548545
42.

Melioidosis in Colombia, description of a clinical case and epidemiological considerations

Rodríguez JY, Álvarez-Moreno CA, Cortés JA, Rodríguez GJ, Esquea K, Pinzón H, Mendoza MJ, Acosta Y.

Biomedica. 2019 May 1;39:10-18. doi: 10.7705/biomedica.v39i3.4534. English, Spanish.

43.

[Cambios significativos en el manejo y control del HIV/sida].

Cortés JA.

Biomedica. 2019 May 1;39:5-9. doi: 10.7705/biomedica.v39i0.5062. Spanish. No abstract available.

44.

GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia.

Belver L, Yang AY, Albero R, Herranz D, Brundu FG, Quinn SA, Pérez-Durán P, Álvarez S, Gianni F, Rashkovan M, Gurung D, Rocha PP, Raviram R, Reglero C, Cortés JR, Cooke AJ, Wendorff AA, Cordó V, Meijerink JP, Rabadan R, Ferrando AA.

Cancer Discov. 2019 Dec;9(12):1774-1791. doi: 10.1158/2159-8290.CD-19-0471. Epub 2019 Sep 13.

PMID:
31519704
45.

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.

Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA.

Future Oncol. 2019 Nov;15(31):3531-3545. doi: 10.2217/fon-2019-0373. Epub 2019 Sep 13.

46.
47.

A Reinforcement-Learning-Based Approach to Enhance Exhaustive Protein Loop Sampling.

Barozet A, Molloy K, Vaisset M, Siméon T, Cortés J.

Bioinformatics. 2019 Aug 29. pii: btz684. doi: 10.1093/bioinformatics/btz684. [Epub ahead of print]

PMID:
31504192
48.

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.

Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E, Cortes J.

Cancer Med. 2019 Nov;8(15):6559-6565. doi: 10.1002/cam4.2545. Epub 2019 Sep 10.

49.

Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory.

Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Fernández-Ferreiro A, Gómez-Lado N, Ruibal Á, Aguiar P; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2019 Dec;84:1-8. doi: 10.1016/j.neurobiolaging.2019.07.014. Epub 2019 Jul 30.

PMID:
31479859
50.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.

Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G, Brunt AM, Kuemmel S, Ruiz I, Perelló A, Kendall A, Brown J, Kristeleit H, Conibear J, Saura C, Grenier J, Máhr K, Schenker M, Sohn J, Lee KS, Shepherd CJ, Oelmann E, Sarker SJ, Prendergast A, Marosics P, Moosa A, Lawrence C, Coetzee C, Mousa K, Cortés J.

JAMA Oncol. 2019 Aug 29. doi: 10.1001/jamaoncol.2019.2526. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center